Research from the UK has found that hip and knee replacements in general last for around three years.

New research has found that exercising on a treadmill helped stroke survivors improve their mobility and physical conditioning.

According to new research by Swedish scientists, older fathers are more likely to have children with bipolar disorder.

Acute pulmonary embolism (PE) is a relatively common cardiovascular emergency. Clots originating in the leg veins may become detached and obstruct the lung vessels. This obstruction may lead to a rise of pressure in the pulmonary circulation and possibly to

Heart failure is a leading cause of death and hospitalisation and represents a major burden on health services. It is estimated that over 15 million people in Europe suffer from heart failure and the syndrome accounts for over 2% of

Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack.

Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single

REGENT is a multicenter, randomized trial for comparison of intracoronary infusion of bone marrow-derived unselected mononuclear cells (MNC) and selected CD34+CXCR4+ cells in 200 patients with acute myocardial infarction and reduced LVEF ¡Ü 40%.

The SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study has investigated the effects of intensive cholesterol lowering with the combination of simvastatin (40 mg daily) and ezetimibe (10 mg daily) in patients with aortic stenosis.

Data from a phase II study of an investigational drug designed to block formation of blood clots show potential for added protection against a second heart attack or stroke among patients who are already taking state-of-the-art prevention therapy.

A twelve month study of treatment with darapladib concluded that,Lp-PLA2 inhibition with darapladib prevented necrotic core expansion, a key determinant of plaque vulnerability.

The management of acute coronary syndromes (with or without ST segment elevation) requires the use of anticoagulants, antiplatelet agents (aspirin, clopidogrel and/or glycoprotein (GP) IIb/IIIa inhibitors), beta-blockers, thrombolytics in some cases, and revascularization / reperfusion.

For patients with acute ST-segment-elevation AMI (STEMI) within 12 hours after symptom onset and with persistent ST-segment elevation, or new or presumednew left bundle-branch block with concomitant ST-segment elevation, restoring coronary blood flow as early as possible is the main

A new study has found that mothers who delivered vaginally compared to caesarean section delivery (CSD) were significantly more responsive to the cry of their own baby, identified through MRI brain scans two to four weeks after delivery.

If there's one thing that everyone knows about newborn babies, it's that they don't sleep through the night, and neither do their parents. But in fact, those first six months of life are crucial to developing the regular sleeping and

The safety debate about drug-eluting stents (DES) is still ongoing. In these times of uncertainty about DES safety, the study has shown that DES markedly improve long-term survival compared to modern bare-metal stents (BMS) implantation in patients with acute ST-segment

One in three people with a high risk of developing cardiovascular disease (CVD) over the next 10 years have not been diagnosed, according to a major study in the September issue of IJCP, the International Journal of Clinical Practice.

Fibrex Medical has announced positive Phase II results for FX06, a peptide for the treatment of reperfusion injury - the damage to heart muscle that results from remedial treatment following a heart attack. The results will be presented at the

Scientists have designed, developed and tested new molecular tools for stem cell research to direct the formation of certain tissue types for use in drug development programmes.

Cordis Corporation has announced the first patient enrollment in the STROLL trial, which will evaluate the safety and efficacy of the S.M.A.R.T. Nitinol Self-Expandable Stent System in treating patients with obstructive superficial femoral artery (SFA) disease, also known as SFA